“Other” ~ Ovarian Cancer — Risk / Phenotype

Factors unrelated to direct standard BRCA1/2 mutations, and those in other major- and moderate-risk genes, on ovarian cancer risk/expression; includes family history, , unusual BRCA1/2 features such as splice-site mutations, SNPs/common polymorphisms, double heterozygotes, etc.,

List was last updated on Oct 10, 2019 @ 2:25 pm.


    • ADP-ribosylation Levels and Patterns Correlate with Gene Expression and Clinical Outcomes in Ovarian Cancers.
    • Conrad LB, Lin KY, Nandu T, Gibson BA, Lea JS, Kraus WL.
    • Mol Cancer Ther. 2019 Oct 8. pii: molcanther.0569.2019. doi: 10.1158/1535-7163.MCT-19-0569. [Epub ahead of print]
    • Epigenetic Risk Assessment of Female Cancers: Women's Information Needs and Attitudes.
    • Rebitschek FG, Reisel D, Lein I, Wegwarth O.
    • Public Health Genomics. 2019 Sep 4;22(1-2):46-57. doi: 10.1159/000501975. [Epub ahead of print]
    • Age-adjusted association of homologous recombination genes with ovarian cancer using clinical exomes as controls.
    • Arvai KJ, Roberts ME, Torene RI, Susswein LR, Marshall ML, Zhang Z, Carter NJ, Yackowski L, Rinella ES, Klein RT, Hruska KS, Retterer K.
    • Hered Cancer Clin Pract. 2019 Jul 15;17:19. doi: 10.1186/s13053-019-0119-3. eCollection 2019.
    • Ovarian cancer risk factors by tumor aggressiveness: An analysis from the Ovarian Cancer Cohort Consortium.
    • Fortner RT, Poole EM, Wentzensen NA, Trabert B, White E, Arslan AA, Patel AV, Setiawan VW, Visvanathan K, Weiderpass E, Adami HO, Black A, Bernstein L, Brinton LA, Buring J, Clendenen TV, Fournier A, Fraser G, Gapstur SM, Gaudet MM, Giles GG, Gram IT, Hartge P, Hoffman-Bolton J, Idahl A, Kaaks R, Kirsh VA, Knutsen S, Koh WP, Lacey JV Jr, Lee IM, Lundin E, Merritt MA, Milne RL, Onland-Moret NC, Peters U, Poynter JN, Rinaldi S, Robien K, Rohan T, Sánchez MJ, Schairer C, Schouten LJ, Tjonneland A, Townsend MK, Travis RC, Trichopoulou A, van den Brandt PA, Vineis P, Wilkens L, Wolk A, Yang HP, Zeleniuch-Jacquotte A, Tworoger SS.
    • Int J Cancer. 2019 Jul 1;145(1):58-69. doi: 10.1002/ijc.32075. Epub 2019 Jan 14.
    • High EMSY expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum.
    • Hollis RL, Churchman M, Michie CO, Rye T, Knight L, McCavigan A, Perren T, Williams ARW, McCluggage WG, Kaplan RS, Jayson GC, Oza A, Harkin DP, Herrington CS, Kennedy R, Gourley C.
    • Cancer. 2019 Jun 2. doi: 10.1002/cncr.32079. [Epub ahead of print]

    Commentary:

    Clarifying the role of EMSY in DNA repair in ovarian cancer

    • Epithelial ovarian cancer risk: a review of the current genetic landscape.
    • Flaum N, Crosbie EJ, Edmondson RJ, Smith MJ, Evans DG.
    • Clin Genet. 2019 May 16. doi: 10.1111/cge.13566. [Epub ahead of print]
    • Review
    • A comprehensive gene-environment interaction analysis in Ovarian Cancer using genome-wide significant common variants.
    • Kim S, Wang M, Tyrer JP, Jensen A, Wiensch A, Liu G, Lee AW, Ness RB, Salvatore M, Tworoger SS, Whittemore AS, Anton-Culver H, Sieh W, Olson SH, Berchuck A, Goode EL, Goodman MT, Doherty JA, Chenevix-Trench G, Rossing MA, Webb PM, Giles GG, Terry KL, Ziogas A, Fortner RT, Menon U, Gayther SA, Wu AH, Song H, Brooks-Wilson A, Bandera EV, Cook LS, Cramer DW, Milne RL, Winham SJ, Kjaer SK, Modugno F, Thompson PJ, Chang-Claude J, Harris HR, Schildkraut JM, Le ND, Wentzensen N, Trabert B, Høgdall E, Huntsman D, Pike MC, Pharoah PDP, Pearce CL, Mukherjee B.
    • Int J Cancer. 2019 May 1;144(9):2192-2205. doi: 10.1002/ijc.32029. Epub 2019 Jan 20.
    • AB0 Blood Group and Ovarian Cancer Survival.
    • Mandato VD, Torricelli F, Mastrofilippo V, Ciarlini G, Pirillo D, Annunziata G, Casali B, Abrate M, Sala GB, Aguzzoli L.
    • J Cancer. 2019 Apr 25;10(9):1949-1957. doi: 10.7150/jca.29272. eCollection 2019.
    • Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk.
    • Lampert EJ, Hays JL, Kohn EC, Annunziata CM, Minasian L, Yu M, Gordon N, Sissung TM, Chiou VL, Figg WD, Houston N, Lee JM.
    • Oncotarget. 2019 Apr 23;10(30):2855-2868. doi: 10.18632/oncotarget.26869. eCollection 2019 Apr 23.
    • Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).
    • Hauke J, Hahnen E, Schneider S, Reuss A, Richters L, Kommoss S, Heimbach A, Marmé F, Schmidt S, Prieske K, Gevensleben H, Burges A, Borde J, De Gregorio N, Nürnberg P, El-Balat A, Thiele H, Hilpert F, Altmüller J, Meier W, Dietrich D, Kimmig R, Schoemig-Markiefka B, Kast K, Braicu E, Baumann K, Jackisch C, Park-Simon TW, Ernst C, Hanker L, Pfisterer J, Schnelzer A, du Bois A, Schmutzler RK, Harter P.
    • J Med Genet. 2019 Apr 12. pii: jmedgenet-2018-105930. doi: 10.1136/jmedgenet-2018-105930. [Epub ahead of print]
    • Genome-wide analysis of common copy number variation and epithelial ovarian cancer risk.
    • Reid BM, Permuth JB, Chen YA, Fridley BL, Iversen ES, Chen Z, Jim H, Vierkant RA, Cunningham JM, Barnholtz-Sloan JS, Narod S, Risch H, Schildkraut JM, Goode EL, Monteiro AN, Sellers TA.
    • Cancer Epidemiol Biomarkers Prev. 2019 Apr 4. pii: cebp.0833.2018. doi: 10.1158/1055-9965.EPI-18-0833. [Epub ahead of print]
    • Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients.
    • Singer CF, Tan YY, Muhr D, Rappaport C, Gschwantler-Kaulich D, Grimm C, Polterauer S, Pfeiler G, Berger A, Tea MM.
    • Cancer Med. 2019 Apr;8(4):1875-1881. doi: 10.1002/cam4.2000. Epub 2019 Mar 1.
    • Ovarian small cell carcinoma in one of a pair of monozygous twins.
    • Fahiminiya S, Sabbaghian N, Albrecht S, Nadaf J, Callegaro-Filho D, Foulkes WD.
    • Fam Cancer. 2019 Apr;18(2):161-163. doi: 10.1007/s10689-018-0108-0.
    • Letter, Case report
    • A 35 Year Old Bangladeshi Lady with Hereditary Mucinous Ovarian Cancer, Complicated with Omental Metastasis.
    • Islam MJ, Roshid B, Pervin S, Kabir S, Chigurupati S, Hasan MN.
    • Mymensingh Med J. 2019 Apr;28(2):484-489.
    • Case report
    • Constitutional Mosaic Epimutations - a hidden cause of cancer?
    • Lønning PE, Eikesdal HP, Løes IM, Knappskog S.
    • Cell Stress. 2019 Mar 22;3(4):118-135. doi: 10.15698/cst2019.04.183.
    • Co-occurrence of Mayer-Rokitansky-Küster-Hauser syndrome and ovarian cancer: A case report and review of the literature.
    • Villa R, Azzollini J, Peissel B, Manoukian S.
    • Gynecol Oncol Rep. 2019 Mar 17;28:68-70. doi: 10.1016/j.gore.2019.03.010. eCollection 2019 May.
    • Shared heritability and functional enrichment across six solid cancers.
    • Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyrer JP, Han Y, Michailidou K, Lesseur C, Kuchenbaecker KB, Dennis J, Conti DV, Casey G, Gaudet MM, Huyghe JR, Albanes D, Aldrich MC, Andrew AS, Andrulis IL, Anton-Culver H, Antoniou AC, Antonenkova NN, Arnold SM, Aronson KJ, Arun BK, Bandera EV, Barkardottir RB, Barnes DR, Batra J, Beckmann MW, Benitez J, Benlloch S, Berchuck A, Berndt SI, Bickeböller H, Bien SA, Blomqvist C, Boccia S, Bogdanova NV, Bojesen SE, Bolla MK, Brauch H, Brenner H, Brenton JD, Brook MN, Brunet J, Brunnström H, Buchanan DD, Burwinkel B, Butzow R, Cadoni G, Caldés T, Caligo MA, Campbell I, Campbell PT, Cancel-Tassin G, Cannon-Albright L, Campa D, Caporaso N, Carvalho AL, Chan AT, Chang-Claude J, Chanock SJ, Chen C, Christiani DC, Claes KBM, Claessens F, Clements J, Collée JM, Correa MC, Couch FJ, Cox A, Cunningham JM, Cybulski C, Czene K, Daly MB, deFazio A, Devilee P, Diez O, Gago-Dominguez M, Donovan JL, Dörk T, Duell EJ, Dunning AM, Dwek M, Eccles DM, Edlund CK, Edwards DRV, Ellberg C, Evans DG, Fasching PA, Ferris RL, Liloglou T, Figueiredo JC, Fletcher O, Fortner RT, Fostira F, Franceschi S, Friedman E, Gallinger SJ, Ganz PA, Garber J, García-Sáenz JA, Gayther SA, Giles GG, Godwin AK, Goldberg MS, Goldgar DE, Goode EL, Goodman MT, Goodman G, Grankvist K, Greene MH, Gronberg H, Gronwald J, Guénel P, Håkansson N, Hall P, Hamann U, Hamdy FC, Hamilton RJ, Hampe J, Haugen A, Heitz F, Herrero R, Hillemanns P, Hoffmeister M, Høgdall E, Hong YC, Hopper JL, Houlston R, Hulick PJ, Hunter DJ, Huntsman DG, Idos G, Imyanitov EN, Ingles SA, Isaacs C, Jakubowska A, James P, Jenkins MA, Johansson M, Johansson M, John EM, Joshi AD, Kaneva R, Karlan BY, Kelemen LE, Kühl T, Khaw KT, Khusnutdinova E, Kibel AS, Kiemeney LA, Kim J, Kjaer SK, Knight JA, Kogevinas M, Kote-Jarai Z, Koutros S, Kristensen VN, Kupryjanczyk J, Lacko M, Lam S, Lambrechts D, Landi MT, Lazarus P, Le ND, Lee E, Lejbkowicz F, Lenz HJ, Leslie G, Lessel D, Lester J, Levine DA, Li L, Li CI, Lindblom A, Lindor NM, Liu G, Loupakis F, Lubiński J, Maehle L, Maier C, Mannermaa A, Marchand LL, Margolin S, May T, McGuffog L, Meindl A, Middha P, Miller A, Milne RL, MacInnis RJ, Modugno F, Montagna M, Moreno V, Moysich KB, Mucci L, Muir K, Mulligan AM, Nathanson KL, Neal DE, Ness AR, Neuhausen SL, Nevanlinna H, Newcomb PA, Newcomb LF, Nielsen FC, Nikitina-Zake L, Nordestgaard BG, Nussbaum RL, Offit K, Olah E, Olama AAA, Olopade OI, Olshan AF, Olsson H, Osorio A, Pandha H, Park JY, Pashayan N, Parsons MT, Pejovic T, Penney KL, Peters WHM, Phelan CM, Phipps AI, Plaseska-Karanfilska D, Pring M, Prokofyeva D, Radice P, Stefansson K, Ramus SJ, Raskin L, Rennert G, Rennert HS, van Rensburg EJ, Riggan MJ, Risch HA, Risch A, Roobol MJ, Rosenstein BS, Rossing MA, De Ruyck K, Saloustros E, Sandler DP, Sawyer EJ, Schabath MB, Schleutker J, Schmidt MK, Setiawan VW, Shen H, Siegel EM, Sieh W, Singer CF, Slattery ML, Sorensen KD, Southey MC, Spurdle AB, Stanford JL, Stevens VL, Stintzing S, Stone J, Sundfeldt K, Sutphen R, Swerdlow AJ, Tajara EH, Tangen CM, Tardon A, Taylor JA, Teare MD, Teixeira MR, Terry MB, Terry KL, Thibodeau SN, Thomassen M, Bjørge L, Tischkowitz M, Toland AE, Torres D, Townsend PA, Travis RC, Tung N, Tworoger SS, Ulrich CM, Usmani N, Vachon CM, Van Nieuwenhuysen E, Vega A, Aguado-Barrera ME, Wang Q, Webb PM, Weinberg CR, Weinstein S, Weissler MC, Weitzel JN, West CML, White E, Whittemore AS, Wichmann HE, Wiklund F, Winqvist R, Wolk A, Woll P, Woods M, Wu AH, Wu X, Yannoukakos D, Zheng W, Zienolddiny S, Ziogas A, Zorn KK, Lane JM, Saxena R, Thomas D, Hung RJ, Diergaarde B, McKay J, Peters U, Hsu L, García-Closas M, Eeles RA, Chenevix-Trench G, Brennan PJ, Haiman CA, Simard J, Easton DF, Gruber SB, Pharoah PDP, Price AL, Pasaniuc B, Amos CI, Kraft P, Lindström S.
    • Nat Commun. 2019 Jan 25;10(1):431. doi: 10.1038/s41467-018-08054-4.
    • The association between non-breast and ovary cancers and BRCA mutation in first- and second-degree relatives of high-risk breast cancer patients: a large-scale study of Koreans.
    • Kim H, Choi DH, Park W, Im YH, Ahn JS, Park YH, Nam SJ, Kim SW, Lee JE, Yu JH, Lee SK, Jung BY.
    • Hered Cancer Clin Pract. 2019 Jan 3;17:1. doi: 10.1186/s13053-018-0103-3. eCollection 2019.
    • Second primary cancer after female breast cancer: Familial risks and cause of death.
    • Zheng G, Hemminki A, Försti A, Sundquist J, Sundquist K, Hemminki K.
    • Cancer Med. 2019 Jan;8(1):400-407. doi: 10.1002/cam4.1899. Epub 2018 Nov 26.
    • The BRCA1 exon 13 duplication: clinical characteristics of 22 families in Northern Sweden.
    • Edwinsdotter Ardnor C, Rosén A, Ljuslinder I, Melin B.
    • Fam Cancer. 2019 Jan;18(1):37-42. doi: 10.1007/s10689-018-0098-y.
    • The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
    • Hjortkjær M, Malik Aagaard Jørgensen M, Waldstrøm M, Ørnskov D, Søgaard-Andersen E, Jakobsen A, Dahl-Steffensen K.
    • Int J Gynecol Cancer. 2019 Jan;29(1):166-173. doi: 10.1136/ijgc-2018-000017.
    • Sequence kernel association test for survival outcomes in the presence of a non-susceptible fraction.
    • Lakhal-Chaieb L, Simard J, Bull S.
    • Biostatistics. 2018 Dec 26. doi: 10.1093/biostatistics/kxy075. [Epub ahead of print]
    • Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
    • Hodgson DR, Dougherty BA, Lai Z, Fielding A, Grinsted L, Spencer S, O'Connor MJ, Ho TW, Robertson JD, Lanchbury JS, Timms KM, Gutin A, Orr M, Jones H, Gilks B, Womack C, Gourley C, Ledermann J, Barrett JC.
    • Br J Cancer. 2018 Nov;119(11):1401-1409. doi: 10.1038/s41416-018-0274-8. Epub 2018 Oct 24.
    • Survival of Women With Type I and II Epithelial Ovarian Cancer Detected by Ultrasound Screening.
    • van Nagell JR Jr, Burgess BT, Miller RW, Baldwin L, DeSimone CP, Ueland FR, Huang B, Chen Q, Kryscio RJ, Pavlik EJ.
    • Obstet Gynecol. 2018 Nov;132(5):1091-1100. doi: 10.1097/AOG.0000000000002921.

    Editorial, Research news:

    Ultrasound Screening for Ovarian Cancer: Are We There Yet?

    • Familial risks of ovarian cancer by age at diagnosis, proband type and histology.
    • Zheng G, Yu H, Kanerva A, Försti A, Sundquist K, Hemminki K.
    • PLoS One. 2018 Oct 3;13(10):e0205000. doi: 10.1371/journal.pone.0205000. eCollection 2018.
    • Borderline Ovarian Tumors Share Familial Risks with Themselves and Invasive Cancers.
    • Zheng G, Yu H, Kanerva A, Försti A, Sundquist K, Hemminki K.
    • Cancer Epidemiol Biomarkers Prev. 2018 Nov;27(11):1358-1363. doi: 10.1158/1055-9965.EPI-18-0503. Epub 2018 Jul 17.
    • Characteristics of African American women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic.
    • Barrington DA, Champion ML, Boitano TKL, Walters-Haygood CL, Farmer MB, Alvarez RD, Estes JM, Leath CA 3rd.
    • Gynecol Oncol. 2018 May;149(2):337-340. doi: 10.1016/j.ygyno.2018.02.014. Epub 2018 Mar 2.
    • Full in-frame exon 3 skipping of BRCA2 confers high risk of breast and/or ovarian cancer.
    • Caputo SM, Léone M, Damiola F, Ehlen A, Carreira A, Gaidrat P, Martins A, Brandão RD, Peixoto A, Vega A, Houdayer C, Delnatte C, Bronner M, Muller D, Castera L, Guillaud-Bataille M, Søkilde I, Uhrhammer N, Demontety S, Tubeuf H, Castelain G; French COVAR group collaborators, Jensen UB, Petitalot A, Krieger S, Lefol C, Moncoutier V, Boutry-Kryza N, Nielsen HR, Sinilnikova O, Stoppa-Lyonnet D, Spurdle AB, Teixeira MR, Coulet F, Thomassen M, Rouleau E.
    • Oncotarget. 2018 Apr 3;9(25):17334-17348. doi: 10.18632/oncotarget.24671. eCollection 2018 Apr 3.
    • Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study.
    • Dixon-Suen SC, Nagle CM, Thrift AP, Pharoah PDP, Ewing A, Pearce CL, Zheng W; Australian Ovarian Cancer Study Group, Chenevix-Trench G, Fasching PA, Beckmann MW, Lambrechts D, Vergote I, Lambrechts S, Van Nieuwenhuysen E, Rossing MA, Doherty JA, Wicklund KG, Chang-Claude J, Jung AY, Moysich KB, Odunsi K, Goodman MT, Wilkens LR, Thompson PJ, Shvetsov YB, Dörk T, Park-Simon TW, Hillemanns P, Bogdanova N, Butzow R, Nevanlinna H, Pelttari LM, Leminen A, Modugno F, Ness RB, Edwards RP, Kelley JL, Heitz F, du Bois A, Harter P, Schwaab I, Karlan BY, Lester J, Orsulic S, Rimel BJ, Kjær SK, Høgdall E, Jensen A, Goode EL, Fridley BL, Cunningham JM, Winham SJ, Giles GG, Bruinsma F, Milne RL, Southey MC, Hildebrandt MAT, Wu X, Lu KH, Liang D, Levine DA, Bisogna M, Schildkraut JM, Berchuck A, Cramer DW, Terry KL, Bandera EV, Olson SH, Salvesen HB, Thomsen LCV, Kopperud RK, Bjorge L, Kiemeney LA, Massuger LFAG, Pejovic T, Bruegl A, Cook LS, Le ND, Swenerton KD, Brooks-Wilson A, Kelemen LE, Lubiński J, Huzarski T, Gronwald J, Menkiszak J, Wentzensen N, Brinton L, Yang H, Lissowska J, Høgdall CK, Lundvall L, Song H, Tyrer JP, Campbell I, Eccles D, Paul J, Glasspool R, Siddiqui N, Whittemore AS, Sieh W, McGuire V, Rothstein JH, Narod SA, Phelan C, Risch HA, McLaughlin JR, Anton-Culver H, Ziogas A, Menon U, Gayther SA, Ramus SJ, Gentry-Maharaj A, Wu AH, Pike MC, Tseng CC, Kupryjanczyk J, Dansonka-Mieszkowska A, Budzilowska A, Rzepecka IK, Webb PM; Ovarian Cancer Association Consortium.
    • Br J Cancer. 2018 Apr;118(8):1123-1129. doi: 10.1038/s41416-018-0011-3. Epub 2018 Mar 20.
    • Common Genetic Variation and Susceptibility to Ovarian Cancer: Current Insights and Future Directions.
    • Kar SP, Berchuck A, Gayther SA, Goode EL, Moysich KB, Pearce CL, Ramus SJ, Schildkraut JM, Sellers TA, Pharoah PDP.
    • Cancer Epidemiol Biomarkers Prev. 2018 Apr;27(4):395-404. doi: 10.1158/1055-9965.EPI-17-0315. Epub 2017 Jun 14.
    • Review, Editorial
    • Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer.
    • Xiao X, Dong D, He W, Song L, Wang O, Yue J, Xie L.
    • Gynecol Oncol. 2018 Apr;149(1):146-154. doi: 10.1016/j.ygyno.2018.02.009. Epub 2018 Mar 1.
    • White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk.
    • Lønning PE, Berge EO, Bjørnslett M, Minsaas L, Chrisanthar R, Høberg-Vetti H, Dulary C, Busato F, Bjørneklett S, Eriksen C, Kopperud R, Axcrona U, Davidson B, Bjørge L, Evans DG, Howell A, Salvesen HB, Janszky I, Hveem K, Romundstad PR, Vatten LJ, Tost J, Dørum A, Knappskog S.
    • Ann Intern Med. 2018 Mar 6;168(5):326-334. doi: 10.7326/M17-0101. Epub 2018 Jan 16.

    Press: Normal-tissue BRCA1 Methylation May Occur Before Birth, Raise Ovarian Cancer Risk. (Medscape/Reuters Health)

    Press: Commentary: Is This 'Provocative Finding' Related to Serous Ovarian Cancer? (Medscape Oncology)

    • White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk: A Perspective.
    • Dobrovic A.
    • Ann Intern Med. 2018 Mar 6;168(5):365-366. doi: 10.7326/M17-3340. Epub 2018 Jan 16.
    • Editorial
    • Breast Cancer is Common in Women With Ovarian Malignant Mixed Mullerian Tumors.
    • Whynott RM, Manahan KJ, Geisler JP.
    • Am J Clin Oncol. 2018 Mar;41(3):286-288. doi: 10.1097/COC.0000000000000266.
    • Does Endometriosis Hinder Successful Ovarian Debulking Surgery?
    • Sananpanichkul P, Muangtan S, Suknikhom W, Bhamarapravatana K, Suwannarurk K.
    • Asian Pac J Cancer Prev. 2018 Feb 26;19(2):509-512.
    • Paternal lineage early onset hereditary ovarian cancers: A Familial Ovarian Cancer Registry study.
    • Eng KH, Szender JB, Etter JL, Kaur J, Poblete S, Huang RY, Zhu Q, Grzesik KA, Battaglia S, Cannioto R, Krolewski JJ, Zsiros E, Frederick PJ, Lele SB, Moysich KB, Odunsi KO.
    • PLoS Genet. 2018 Feb 15;14(2):e1007194. doi: 10.1371/journal.pgen.1007194. eCollection 2018 Feb.
    • Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma.
    • Bernards SS, Pennington KP, Harrell MI, Agnew KJ, Garcia RL, Norquist BM, Swisher EM.
    • Gynecol Oncol. 2018 Feb;148(2):281-285. doi: 10.1016/j.ygyno.2017.12.004. Epub 2017 Dec 9.
    • Integrated microRNA and mRNA signatures in peripheral blood lymphocytes of familial epithelial ovarian cancer.
    • Dou YD, Huang T, Wang Q, Shu X, Zhao SG, Li L, Liu T, Lu G, Chan WY, Liu HB.
    • Biochem Biophys Res Commun. 2018 Jan 29;496(1):191-198. doi: 10.1016/j.bbrc.2018.01.023. Epub 2018 Jan 4.
    • Lifestyle and Reproductive Factors and Ovarian Cancer Risk by p53 and MAPK Expression.
    • Harris HR, Rice MS, Shafrir AL, Poole EM, Gupta M, Hecht JL, Terry KL, Tworoger SS.
    • Cancer Epidemiol Biomarkers Prev. 2018 Jan;27(1):96-102. doi: 10.1158/1055-9965.EPI-17-0609. Epub 2017 Nov 13.
    • Familial associations of male breast cancer with other cancers.
    • Zheng G, Yu H, Hemminki A, Försti A, Sundquist K, Hemminki K.
    • Breast Cancer Res Treat. 2017 Dec;166(3):897-902. doi: 10.1007/s10549-017-4468-1. Epub 2017 Aug 23.
    • Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction.
    • Jones MR, Kamara D, Karlan BY, Pharoah PDP, Gayther SA.
    • Gynecol Oncol. 2017 Dec;147(3):705-713. doi: 10.1016/j.ygyno.2017.10.001. Epub 2017 Oct 18.
    • Review
    • Dermatomyositis - key to diagnosing ovarian cancer, monitoring treatment and detecting recurrent disease: Case report.
    • Field C, Goff BA.
    • Gynecol Oncol Rep. 2017 Nov 28;23:1-3. doi: 10.1016/j.gore.2017.11.009. eCollection 2018 Feb.
    • Increased single-strand annealing rather than non-homologous end-joining predicts hereditary ovarian carcinoma.
    • Deniz M, Romashova T, Kostezka S, Faul A, Gundelach T, Moreno-Villanueva M, Janni W, Friedl TWP, Wiesmüller L.
    • Oncotarget. 2017 Oct 9;8(58):98660-98676. doi: 10.18632/oncotarget.21720. eCollection 2017 Nov 17.
    • Two sisters with Mayer-Rokitansky-Küster-Hauser syndrome and serous adenocarcinoma of the ovary.
    • Huepenbecker SP, Divine L, Chu CS, Mutch DG.
    • Gynecol Oncol Rep. 2017 Sep 7;22:13-15. doi: 10.1016/j.gore.2017.09.002. eCollection 2017 Nov.
    • The association between prognosis of breast cancer and first-degree family history of breast or ovarian cancer: a systematic review and meta-analysis.
    • Song JL, Chen C, Yuan JP, Sun SR.
    • Fam Cancer. 2017 Jul;16(3):339-349. doi: 10.1007/s10689-017-9969-x.
    • Review
    • Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
    • Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, Goldgar DE, Terry MB, Rookus MA, Easton DF, Antoniou AC; and the BRCA1 and BRCA2 Cohort Consortium, McGuffog L, Evans DG, Barrowdale D, Frost D, Adlard J, Ong KR, Izatt L, Tischkowitz M, Eeles R, Davidson R, Hodgson S, Ellis S, Nogues C, Lasset C, Stoppa-Lyonnet D, Fricker JP, Faivre L, Berthet P, Hooning MJ, van der Kolk LE, Kets CM, Adank MA, John EM, Chung WK, Andrulis IL, Southey M, Daly MB, Buys SS, Osorio A, Engel C, Kast K, Schmutzler RK, Caldes T, Jakubowska A, Simard J, Friedlander ML, McLachlan SA, Machackova E, Foretova L, Tan YY, Singer CF, Olah E, Gerdes AM, Arver B, Olsson H./li>
    • JAMA. 2017 Jun 20;317(23):2402-2416. doi: 10.1001/jama.2017.7112.

    Research news:

    Family history is strong risk factor in BRCA1 and BRCA2 carriers, study finds.

    Research news:

    Genetics: BRCA-mutant breast/ovarian cancer revealed.

    Press: Breast and ovarian cancers: Large study improves estimates of genetic risk. (Medical News Today)

    Press: Most Precise Estimates Ever of Cancer Risks With BRCA. (Medscape)

    • Common Genetic Variation and Susceptibility to Ovarian Cancer: Current Insights and Future Directions.
    • Kar SP, Berchuck A, Gayther SA, Goode EL, Moysich KB, Pearce CL, Ramus SJ, Schildkraut JM, Sellers TA, Pharoah PDP.
    • Cancer Epidemiol Biomarkers Prev. 2017 Jun 14. pii: cebp.0315.2017. doi: 10.1158/1055-9965.EPI-17-0315. [Epub ahead of print]
    • Review
    • [Reflections on treatments for infertility and the possible occurrence of ovarian carcinomas.]
    • Ferranti G, Prosperi Porta R, La Rosa VL, Vitale SG, Laganà AS.
    • Recenti Prog Med. 2017 Mar;108(3):136-140. doi: 10.1701/2656.27236.
    • Commentary, [Article in Italian]
    • Differences in survival for patients with familial and sporadic cancer.
    • Lee M, Reilly M, Lindström LS, Czene K.
    • Int J Cancer. 2017 Feb 1;140(3):581-590. doi: 10.1002/ijc.30476. Epub 2016 Nov 3.
    • An ovarian mass after breast cancer: Metachronous carcinoma or metastasis? A case report.
    • Makris GM, Marinelis A, Battista MJ, Chrelias C, Papantoniou N.
    • Int J Surg Case Rep. 2017;31:106-108. doi: 10.1016/j.ijscr.2016.12.022. Epub 2016 Dec 30.
    • Do Ovarian Cancer Patients with a Family History of Cancer (Suspected BRCA1 or BRCA2 Mutation) Suffer Greater Chemotherapy Toxicity?
    • Egloff H, Jatoi A.
    • Cancer Invest. 2016 Nov 25;34(10):531-535. Epub 2016 Oct 28.
    • Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium.
    • Wentzensen N, Poole EM, Trabert B, White E, Arslan AA, Patel AV, Setiawan VW, Visvanathan K, Weiderpass E, Adami HO, Black A, Bernstein L, Brinton LA, Buring J, Butler LM, Chamosa S, Clendenen TV, Dossus L, Fortner R, Gapstur SM, Gaudet MM, Gram IT, Hartge P, Hoffman-Bolton J, Idahl A, Jones M, Kaaks R, Kirsh V, Koh WP, Lacey JV Jr, Lee IM, Lundin E, Merritt MA, Onland-Moret NC, Peters U, Poynter JN, Rinaldi S, Robien K, Rohan T, Sandler DP, Schairer C, Schouten LJ, Sjöholm LK, Sieri S, Swerdlow A, Tjonneland A, Travis R, Trichopoulou A, van den Brandt PA, Wilkens L, Wolk A, Yang HP, Zeleniuch-Jacquotte A, Tworoger SS.
    • J Clin Oncol. 2016 Aug 20;34(24):2888-98. doi: 10.1200/JCO.2016.66.8178. Epub 2016 Jun 20.
    • Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers.
    • Streff H, Profato J, Ye Y, Nebgen D, Peterson SK, Singletary C, Arun BK, Litton JK.
    • Oncologist. 2016 Jul;21(7):869-74. doi: 10.1634/theoncologist.2015-0354. Epub 2016 Jun 15.
    • Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study.
    • Dixon SC, Nagle CM, Thrift AP, Pharoah PD, Pearce CL, Zheng W, Painter JN, Chenevix-Trench AG, Fasching PA, Beckmann MW, Lambrechts D, Vergote I, Lambrechts S, Van Nieuwenhuysen E, Rossing MA, Doherty JA, Wicklund KG, Chang-Claude J, Rudolph A, Moysich KB, Odunsi K, Goodman MT, Wilkens LR, Thompson PJ, Shvetsov YB, Dörk T, Park-Simon TW, Hillemanns P, Bogdanova N, Butzow R, Nevanlinna H, Pelttari LM, Leminen A, Modugno F, Ness RB, Edwards RP, Kelley JL, Heitz F, Karlan BY, Kjær SK, Høgdall E, Jensen A, Goode EL, Fridley BL, Cunningham JM, Winham SJ, Giles GG, Bruinsma F, Milne RL, Southey MC, Hildebrandt MA, Wu X, Lu KH, Liang D, Levine DA, Bisogna M, Schildkraut JM, Berchuck A, Cramer DW, Terry KL, Bandera EV, Olson SH, Salvesen HB, Thomsen LC, Kopperud RK, Bjorge L, Kiemeney LA, Massuger LF, Pejovic T, Cook LS, Le ND, Swenerton KD, Brooks-Wilson A, Kelemen LE, Lubiński J, Huzarski T, Gronwald J, Menkiszak J, Wentzensen N, Brinton L, Yang H, Lissowska J, Høgdall CK, Lundvall L, Song H, Tyrer JP, Campbell I, Eccles D, Paul J, Glasspool R, Siddiqui N, Whittemore AS, Sieh W, McGuire V, Rothstein JH, Narod SA, Phelan C, Risch HA, McLaughlin JR, Anton-Culver H, Ziogas A, Menon U, Gayther SA, Ramus SJ, Gentry-Maharaj A, Wu AH, Pike MC, Tseng CC, Kupryjanczyk J, Dansonka-Mieszkowska A, Budzilowska A, Spiewankiewicz B, Webb PM; Ovarian Cancer Association Consortium.
    • Int J Epidemiol. 2016 Jun;45(3):884-95. doi: 10.1093/ije/dyw158. Epub 2016 Jul 10.
    • Outcomes of Incidental Fallopian Tube High-Grade Serous Carcinoma and Serous Tubal Intraepithelial Carcinoma in Women at Low Risk of Hereditary Breast and Ovarian Cancer.
    • Chay WY, McCluggage WG, Lee CH, Köbel M, Irving J, Millar J, Gilks CB, Tinker AV.
    • Int J Gynecol Cancer. 2016 Mar;26(3):431-6. doi: 10.1097/IGC.0000000000000639.
    • Hypodontia and ovarian cancer: A systematic review.
    • Iavazzo C, Papakiritsis M, Gkegkes ID.
    • J Turk Ger Gynecol Assoc. 2016 Jan 12;17(1):41-4. doi: 10.5152/jtgga.2015.15174. eCollection 2016.
    • Identifying post-menopausal women at elevated risk for epithelial ovarian cancer.
    • Urban N, Hawley S, Janes H, Karlan BY, Berg CD, Drescher CW, Manson JE, Palomares MR, Daly MB, Wactawski-Wende J, O'Sullivan MJ, Thorpe J, Robinson RD, Lane D, Li C, Anderson GL.
    • Gynecol Oncol. 2015 Nov;139(2):253-260. doi: 10.1016/j.ygyno.2015.08.024. Epub 2015 Sep 3.
    • Shared genetics underlying epidemiological association between endometriosis and ovarian cancer.
    • Lu Y, Cuellar-Partida G, Painter JN, Nyholt DR; Australian Ovarian Cancer Study; International Endogene Consortium (IEC), Morris AP, Fasching PA, Hein A, Burghaus S, Beckmann MW, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Vanderstichele A, Doherty JA, Rossing MA, Wicklund KG, Chang-Claude J, Eilber U, Rudolph A, Wang-Gohrke S, Goodman MT, Bogdanova N, Dörk T, Dürst M, Hillemanns P, Runnebaum IB, Antonenkova N, Butzow R, Leminen A, Nevanlinna H, Pelttari LM, Edwards RP, Kelley JL, Modugno F, Moysich KB, Ness RB, Cannioto R, Høgdall E, Jensen A, Giles GG, Bruinsma F, Kjaer SK, Hildebrandt MA, Liang D, Lu KH, Wu X, Bisogna M, Dao F, Levine DA, Cramer DW, Terry KL, Tworoger SS, Missmer S, Bjorge L, Salvesen HB, Kopperud RK, Bischof K, Aben KK, Kiemeney LA, Massuger LF, Brooks-Wilson A, Olson SH, McGuire V, Rothstein JH, Sieh W, Whittemore AS, Cook LS, Le ND, Gilks CB, Gronwald J, Jakubowska A, Lubiński J, Gawełko J, Song H, Tyrer JP, Wentzensen N, Brinton L, Trabert B, Lissowska J, Mclaughlin JR, Narod SA, Phelan C, Anton-Culver H, Ziogas A, Eccles D, Gayther SA, Gentry-Maharaj A, Menon U, Ramus SJ, Wu AH, Dansonka-Mieszkowska A, Kupryjanczyk J, Timorek A, Szafron L, Cunningham JM, Fridley BL, Winham SJ, Bandera EV, Poole EM, Morgan TK, Risch HA, Goode EL, Schildkraut JM, Webb PM, Pearce CL, Berchuck A, Pharoah PD, Montgomery GW, Zondervan KT, Chenevix-Trench G, MacGregor S.
    • Hum Mol Genet. 2015 Oct 15;24(20):5955-64. doi: 10.1093/hmg/ddv306. Epub 2015 Jul 30.
    • Genetic testing for RAD51C mutations: in the clinic and community.
    • Sopik V, Akbari MR, Narod SA.
    • Clin Genet. 2015 Oct;88(4):303-12. doi: 10.1111/cge.12548. Epub 2015 Jan 7.
    • Review
    • Ovarian cancer in BRCA1/2 mutation carriers: The impact of mutation position and family history on the cancer risk.
    • Teixeira N, Mourits MJ, Vos JR, Kolk DM, Jansen L, Oosterwijk JC, Bock GH.
    • Maturitas. 2015 Oct;82(2):197-202. doi: 10.1016/j.maturitas.2015.07.001. Epub 2015 Jul 9.
    • A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects.
    • Jervis S, Song H, Lee A, Dicks E, Harrington P, Baynes C, Manchanda R, Easton DF, Jacobs I, Pharoah PP, Antoniou AC.
    • J Med Genet. 2015 Jul;52(7):465-75. doi: 10.1136/jmedgenet-2015-103077. Epub 2015 May 29.

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: ovarian cancer risk based on family history

    • BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients - A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).
    • Ruscito I, Dimitrova D, Vasconcelos I, Gellhaus K, Schwachula T, Bellati F, Zeillinger R, Benedetti-Panici P, Vergote I, Mahner S, Cacsire-Tong D, Concin N, Darb-Esfahani S, Lambrechts S, Sehouli J, Olek S, Braicu EI.
    • Eur J Cancer. 2014 Aug;50(12):2090-8. doi: 10.1016/j.ejca.2014.05.001. Epub 2014 Jun 2.
    • Is there a link between ovarian cancer and tooth agenesis?
    • Bonds J, Pollan-White S, Xiang L, Mues G, D'Souza R.
    • Eur J Med Genet. 2014 Apr;57(5):235-9. doi: 10.1016/j.ejmg.2014.02.013. Epub 2014 Mar 12.
    • Oral contraceptive and reproductive risk factors for ovarian cancer within sisters in the breast cancer family registry.
    • Ferris JS, Daly MB, Buys SS, Genkinger JM, Liao Y, Terry MB.
    • Br J Cancer. 2014 Feb 18;110(4):1074-80. doi: 10.1038/bjc.2013.803. Epub 2014 Jan 7.
    • Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants.
    • Jervis S, Song H, Lee A, Dicks E, Tyrer J, Harrington P, Easton DF, Jacobs IJ, Pharoah PP, Antoniou AC.
    • J Med Genet. 2014 Feb;51(2):108-13. doi: 10.1136/jmedgenet-2013-102015. Epub 2013 Nov 25.
    • Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility.
    • Rizzuto I, Behrens RF, Smith LA.
    • Cochrane Database Syst Rev. 2013 Aug 13;(8):CD008215. doi: 10.1002/14651858.CD008215.pub2.
    • Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2.
    • Ingham SL, Warwick J, Buchan I, Sahin S, O'Hara C, Moran A, Howell A, Evans DG.
    • J Med Genet. 2013 Jun;50(6):368-72. doi: 10.1136/jmedgenet-2013-101607. Epub 2013 Mar 28.

    Research News:

    BRCA1/2 negative status predicts no extended risk of invasive ovarian cancer.

    • In vitro fertilization is associated with an increased risk of borderline ovarian tumours.
    • Stewart LM, Holman CD, Finn JC, Preen DB, Hart R.
    • Gynecol Oncol. 2013 May;129(2):372-6. doi: 10.1016/j.ygyno.2013.01.027. Epub 2013 Feb 4.
    • Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testing.
    • Norquist BM, Pennington KP, Agnew KJ, Harrell MI, Pennil CC, Lee MK, Casadei S, Thornton AM, Garcia RL, Walsh T, Swisher EM.
    • Gynecol Oncol. 2013 Mar;128(3):483-7. doi: 10.1016/j.ygyno.2012.12.015. Epub 2012 Dec 19.
    • In vitro fertilization, endometriosis, nulliparity and ovarian cancer risk.
    • Stewart LM, Holman CD, Aboagye-Sarfo P, Finn JC, Preen DB, Hart R.
    • Gynecol Oncol. 2013 Feb;128(2):260-4. doi: 10.1016/j.ygyno.2012.10.023. Epub 2012 Oct 29.
    • Epigenetic inactivation of BRCA1 through promoter hypermethylation in ovarian cancer progression.
    • Wang YQ, Yan Q, Zhang JR, Li SD, Yang YX, Wan XP.
    • J Obstet Gynaecol Res. 2013 Feb;39(2):549-54. doi: 10.1111/j.1447-0756.2012.01979.x. Epub 2012 Sep 25.
    • Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens.
    • Reitsma W, de Bock GH, Oosterwijk JC, Bart J, Hollema H, Mourits MJ.
    • Eur J Cancer. 2013 Jan;49(1):132-41. doi: 10.1016/j.ejca.2012.07.021. Epub 2012 Aug 21.
    • Germline copy number variation and ovarian cancer survival.
    • Fridley BL, Chalise P, Tsai YY, Sun Z, Vierkant RA, Larson MC, Cunningham JM, Iversen ES, Fenstermacher D, Barnholtz-Sloan J, Asmann Y, Risch HA, Schildkraut JM, Phelan CM, Sutphen R, Sellers TA, Goode EL.
    • Front Genet. 2012 Aug 8;3:142. doi: 10.3389/fgene.2012.00142. eCollection 2012.
    • Shorter telomere length is associated with increased ovarian cancer risk in both familial and sporadic cases.
    • Martinez-Delgado B, Yanowsky K, Inglada-Perez L, de la Hoya M, Caldes T, Vega A, Blanco A, Martin T, Gonzalez-Sarmiento R, Blasco M, Robledo M, Urioste M, Song H, Pharoah P, Benitez J.
    • J Med Genet. 2012 May;49(5):341-4. Epub 2012 Apr 6.

    Free Full Text: Shorter Telomere Length Is Associated With Increased Ovarian Cancer Risk in Both Familial and Sporadic Cases. (Medscape Oncology)

    • Appendectomy and cancer risk in Jewish BRCA1 and BRCA2 mutation carriers.
    • Bernholtz S, Jakobson-Setton A, Korach J, Ben Baruch G, Laitman Y, Friedman E.
    • Breast Cancer Res Treat. 2012 Feb;131(3):981-5. doi: 10.1007/s10549-011-1807-5. Epub 2011 Oct 9.